The stock of Diffusion Pharmaceuticals Inc. (NASDAQ:DFFN) is now priced at $0.91 and the shares are -0.07 points down or -7.1% lower compared to its previous closing price of $0.98. The stock had 2.799 million contracts set over the past session. DFFN shares’ daily volume is compared to its average trading volume at 2.938 million shares. However, it has a float of 63.83 million and although its performance was -13.33% over the week, it’s one to watch. It means the stock’s downside potential is -100% with the DFFN share price recently placing at $0.88 to $0.9679. However, some brokerage firms have priced the stock below the average, including one that has called $3.5.

The shorts are running away from the Diffusion Pharmaceuticals Inc. stock, with the latest data on short interest released on August 14, 2020, showing that short interest numbers in the DFFN shares have declined. Short interest in the stock represents just 0.91% of its float, but the volume has dropped by -158327. The volume of shorted shares dropped to 579045 from 737372 shares over the last two weeks. The average intraday trading volume has been 1.363 million shares, which means that days to cover moved to roughly 1.

In the last trading session, Diffusion Pharmaceuticals Inc. (NASDAQ:DFFN) dropped by -$0.14 over the week and lost -$0.23 on its 20-day. The stock’s high in the recent session is lower when compared to its 52-week high of $2.27. The stock recorded its established 52-week high on 09/16/19.

Since 11/18/19, the stock has traded to a low of $0.211 at 331.28%, an encouraging piece of data likely to interest most investors out to exploit the stock’s recent surge. The stock has a beta allocation of 1.26. Being above 1 means that the stock’s volatility is higher than the market and traders are keenly watching it.

Looking at current readings, Diffusion Pharmaceuticals Inc.’s two-week RSI is 37.29. This suggests that the stock is neutral at the moment and that DFFN shares’ price movement remains stable. The stochastic readings are equally revealing at 20.72% meaning the DFFN share price is currently in overbought territory.

The technical chart shows that the DFFN stock will likely settle at between $0.9586 and $1.0072 per share. However, if the stock dips below $0.8707, then its market would become much weaker. Any downside could see the stock price sliding to levels as low as $0.8314.

Currently, the stock is trading in the red of MACD, with a reading of -0.0627. Investors always pay attention to any move above or below the zero-line, mainly because the indicator points to the position of the stock’s short-term average relative to its long-term measure. A MACD -a reading above the zero line means that the short-term is above the long-term average. This scenario implies that there is an upward momentum. The opposite is true when the MACD falls below the zero-line.

Analysts at Maxim Group assigned DFFN a rating of Buy in their intiating review released on March 21.

The average rating for the DFFN equity is 2 and is currently gathering a bullish momentum. Of 1 analysts tracking Diffusion Pharmaceuticals Inc. polled by Reuters, 0 rated DFFN as a hold. The remaining 1 analysts were split evenly. However, the split wasn’t equal as a majority (1) rated it as a buy or strong buy. 0 analyst advised investors against buying the stock or to sell if they own any of the stock.